北京弘润天源生物技术有限公司

logo

　　北京弘润天源生物技术有限公司是专门从事细胞治疗技术研究与细胞治疗临床应用的专业化生物技术公司，是北京市中关村高新技术企业、北京市海淀区创新企业。公司以北京大学技术团队为核心。公司主要致力于人成体干细胞、树突状细胞治疗的研究与应用，通过与临床医院的全面合作，开展细胞治疗的临床应用服务。
　　目前公司拥有符合临床治疗需要的全部细胞类型，包括神经干细胞、视网膜上皮祖细胞、脐带和自体骨髓间充质干细胞、肝脏干细胞、树突状细胞和细胞因子诱导的杀伤细胞，是技术平台最完整的公司之一。其中神经干细胞贴壁培养技术、视网膜上皮祖细胞培养技术、肝脏干细胞培养技术、肿瘤干细胞培养技术、放化疗耐药细胞培养技术在国内外均为领先。公司已就肿瘤干细胞及肿瘤干细胞疫苗申报国家专利（专利申请号：200910082778.0，200910083085.3）
　　公司秉承“为细胞治疗事业的发展实施最好推广、追求最佳服务”的运营理念，围绕临床治疗的细胞供应和临床服务两个环节，以技术支持、细胞供应、科研服务（临床研究和咨询、课题合作）为服务方式，结合构建各地区生产中心的细胞生产网络为运营模式，实现产业化发展。
　　公司拥有通过SFDA认证的GMP生产车间并配置先进的细胞生产设备，拥有系统的细胞生产管理规范与管理制度，为细胞的临床应用提供了有效的保障。
　　公司作为一家运作细胞治疗的高科技生物公司，有着清晰的管理组织结构和一大批优秀人才。在技术方面拥有多项领先的专利技术和一批高端的技术专家团队；在临床方面我们与国内多所医院的一批临床专家形成密切合作，积极推进各类疾病的规范化细胞治疗。公司现阶段的细胞治疗范围主要集中在：成体干细胞治疗神经系统疾病、骨科疾病、外周血管病；树突状细胞治疗恶性肿瘤。

公司官网：www.cellonis.com

Cellonis Biotechnologies Group is a China based biotechnology company focus primarily on the development and applying of novel stem cell technologies for providing the effective, patient-specific therapies to patients with degenerative central nervous system (CNS) disorders, cardiovascular diseases, liver diseases and cancers.

Based on the over 5 years experience of extensive research and treatment protocol development, we have built up an advance stem cell platform technology and more than 5 stem cell therapy programs have been used by partner hospitals for clinical research and treatment.

We have gotten the promising results from the clinical trails with our lead autologous adult stem cell and neural stem cell therapy programs for different kinds of CNS disorders such as parkinson's disease, post stroke, cerebral palsy, ALS (motor neuron disease), MS (multiple sclerosis), brain injury and spinal cord injury (SCI). And more than 100 patients experienced the stem cell therapy with our therapy programs. In addition to our CNS disorder programs, we are developing stem cell approaches for other conditions, including the liver diseases（hepatitis and cirrhosis.）, heart failure and peripheral artery diseases.

Cellonis is also advancing the cancer vaccine and cellular therapy for cancer. Our cancer vaccine programs which target at different kinds of solid tumor cells have showed great potential in cancer treatment. Currently Cellonis is exploring the novel cell therapies with the integration of its core stem cell technologies and immune technologies. The patented technologies will allow Cellonis to develop more effective cellular approaches for cancer relapse and metastasis.

Our headquarters and main facilities are located in Beijing. SinoTopCell Limited is a wholly-owned subsidiary of Cellonis located in Hong Kong focus on the international technology development and collaboration.

web site:www.cellonis.com